AK 106 001616

Drug Profile

AK 106 001616

Alternative Names: AK-106; AK106-001616

Latest Information Update: 22 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asahi Kasei
  • Class Analgesics; Anti-inflammatories; Antirheumatics
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 30 Jul 2015 Phase-II development for Rheumatoid arthritis is ongoing in Europe
  • 30 Jul 2015 NDR project - Asahi Kissei, AR 2014 (pipeline of May 2014) - pII (overseas) for RA - http://www.asahi-kasei.co.jp/asahi/en/ir/annual/14en.pdf; no latest pipeline
  • 06 Apr 2012 Asahi Kasei Pharma Corporation completes a phase II trial in Rheumatoid arthritis in Czech Republic, Germany, Hungary, Poland, Slovakia, Ukraine and United Kingdom (NCT01285752)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top